Page 16 - Clinical Research Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

An estimated 20 million US women (and 10 million US men) will have an eating disorder at some point in their lives, says the National Eating Disorders Association (NEDA). While the exact cause of eating disorders is unknown, they are believed to develop out of a combination of biological, psychological, and sociocultural factors. Every eating disorder has its own set of symptoms and side effects. Here, clinicians provide a rundown of recognized eating disorders that you should know about. Anorexia nervosa An anorexia nervosa diagnosis involves three main components. One, ...

Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD Algernon Pharmaceuticals Inc.  a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company’s New DMT Stroke Clinical Research Program on an upcoming BioPub webcast. The webcast will be held Wednesday February 3, 2021 hosted by Dr. KSS at Noon EST. The Company invites interested shareholders, … Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: A...

Researchers develop patient-informed questionnaire tool for ventral hernia repair surgery patients Patient-reported outcomes have become a critical part of improving surgical care because of their ability to capture patient experiences, such as quality of life and satisfaction, that can help inform treatment. However, for patients undergoing abdominal hernia repair -- a common procedure performed on about 400,000 patients a year in the United States -- a tool to effectively and practically measure those outcomes has not been widely accepted and implemented by clinics. Now, researchers from th...

Algernon Pharmaceuticals Provides Year End Summary of Key Activities Algernon Pharmaceuticals Inc.  a clinical stage pharmaceutical development company, is pleased to provide a summary of the Company’s key activities this past calendar year. NP-120 Idiopathic Pulmonary Fibrosis & Chronic Cough Clinical Research Program March 30 – Submitted for ethics approval in Australia for a Phase 2 study of the Company’s re-purposed drug Ifenprodil for IPF and chronic cough. May 6 – … Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon...